Postpartum depression, or depression in women within 12 months of giving birth, is common. It affects one-quarter of these women, which is why current recommendations are to begin screening for depression during pregnancy. Left un- and under-treated, the mother, newborn, and family are at risk for relationship problems, psychiatric illness, and other consequences. In this 1-hour, case-based activity, developed by family medicine and mental health clinicians, team-based screening recommendations, along with strategies for overcoming barriers in diagnosis, are applied to primary care practice. The risks and benefits of treatment, including nonpharmacologic and pharmacologic options, such as selective serotonin reuptake inhibitors and neuroactive steroid gamma-aminobutyric acid A receptor positive modulators, are discussed, to enable the development of a personalized care plan using a collaborative care model.
Course Credit:
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
0.50 Pharmacology Hours
Dates:
Opens: 2024-05-24
Closes: 2025-05-24
Target Audience:
This activity was developed for primary care physicians and advanced practice providers.
This activity is supported by educational grants from Sage Therapeutics, Inc.
-
Anita H. Clayton, MD
Wilford W. Spradlin Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor, Clinical Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia -
Sarah Nagle-Yang, MD
Vice Chair for Quality
Deputy Executive Director, Colorado Center for Women's Behavioral Health
Associate Professor of Psychiatry
University of Colorado School of Medicine
Aurora, Colorado -
Barbara P. Yawn, MD
Adjunct Professor
University of Minnesota
Department of Family and Community Health
Minneapolis, Minnesota
